Skip to main content
Erschienen in: Supportive Care in Cancer 9/2015

01.09.2015 | Original Article

Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema

verfasst von: Sibel Eyigör, Ece Cinar, Ismail Caramat, Burcu Koc Unlu

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In clinical practice, noticeable differences are seen in patient response to the treatment of breast cancer-related lymphedema. Although some factors influencing response to treatment are mentioned in the literature, there is no sufficient evidence and results are confusing. For this reason, our objective in this study is to identify predictive and response-related factors for response to treatment of breast cancer-related lymphedema.

Methods

We analyzed data retrospectively from the files of patients with breast cancer-related lymphedema between 2006 and 2012. Patient demographics, clinical variables, and patient variables were recorded. Circumference measurements of lymphedema and healthy arms were recorded. We used a computer program (Limb Volumes Professional version 5.0) to transform these values to limb volumes in milliliters.

Results

The average age of 331 patients was 54.4 ± 10.9. The average length of lymphedema treatment was 2.92 ± 1.3 weeks. A statistically significant positive correlation was found between postoperative weight gain and postoperative duration, number of chemotherapy (CT) cycles, duration of tamoxifen use, and duration of hormonal therapy (p < 0.05). There was a statistically significant negative correlation between posttreatment arm volume and activity level, postoperative duration, and postoperative weight gain (p < 0.05).

Conclusion

The treatment methods used for treating breast cancer had no effect on the response to treatment of lymphedema. Weight gain during the treatment of breast cancer is important for both the development of lymphedema and the response to treatment. When treating breast cancer-related lymphedema, the relationship between activity level and postoperative weight gain may provide us guidance in clinical practice.
Literatur
1.
Zurück zum Zitat Salonen P, Rantanen A, Kellokumpu-Lehtinen PL, Huhtala H, Kaunonen M (2014) The quality of life and social support in significant others of patients with breast cancer—a longitudinal study. Eur J Cancer Care (Engl) 23(2):274–283CrossRef Salonen P, Rantanen A, Kellokumpu-Lehtinen PL, Huhtala H, Kaunonen M (2014) The quality of life and social support in significant others of patients with breast cancer—a longitudinal study. Eur J Cancer Care (Engl) 23(2):274–283CrossRef
2.
Zurück zum Zitat International Society of Lymphology (2013) The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 46:1–11 International Society of Lymphology (2013) The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 46:1–11
3.
Zurück zum Zitat Paiva DM, Rodrigues VO, Cesca MG et al (2013) Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil. BMC Womens Health 13:6PubMedCentralPubMedCrossRef Paiva DM, Rodrigues VO, Cesca MG et al (2013) Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil. BMC Womens Health 13:6PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Vignes S, Porcher R, Champagne A et al (2006) Predictive factors of response to intensive decongestive physiotherapy in upper limb lymphedema after breast cancer treatment: a cohort study. Breast Cancer Res Treat 98(1):1–6PubMedCrossRef Vignes S, Porcher R, Champagne A et al (2006) Predictive factors of response to intensive decongestive physiotherapy in upper limb lymphedema after breast cancer treatment: a cohort study. Breast Cancer Res Treat 98(1):1–6PubMedCrossRef
5.
Zurück zum Zitat Miaskowski C, Dodd M, Paul SM et al (2013) Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One 8:e60164PubMedCentralPubMedCrossRef Miaskowski C, Dodd M, Paul SM et al (2013) Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One 8:e60164PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Stewart FW, Treves N (1948) Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1:64–81PubMedCrossRef Stewart FW, Treves N (1948) Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1:64–81PubMedCrossRef
7.
Zurück zum Zitat Forner-Cordero I, Munoz-Langa J, Forner-Cordero A et al (2010) Predictive factors of response to decongestive therapy in patients with breast-cancer-related lymphedema. Ann Surg Oncol 17(3):744–751PubMedCrossRef Forner-Cordero I, Munoz-Langa J, Forner-Cordero A et al (2010) Predictive factors of response to decongestive therapy in patients with breast-cancer-related lymphedema. Ann Surg Oncol 17(3):744–751PubMedCrossRef
8.
Zurück zum Zitat Liao SF, Li SH, Huang HY et al (2013) The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of lymphedema severity and response to CDP in breast cancer-related lymphedema (BCRL). Breast (Edinburgh, Scotland) 22:703–706CrossRef Liao SF, Li SH, Huang HY et al (2013) The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of lymphedema severity and response to CDP in breast cancer-related lymphedema (BCRL). Breast (Edinburgh, Scotland) 22:703–706CrossRef
9.
10.
Zurück zum Zitat Tobin MB, Lacey HJ, Meyer L et al (1993) The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 72:3248–3252PubMedCrossRef Tobin MB, Lacey HJ, Meyer L et al (1993) The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 72:3248–3252PubMedCrossRef
11.
Zurück zum Zitat Erickson VS, Pearson ML, Ganz PA et al (2001) Arm edema in breast cancer patients. J Natl Cancer Inst 93:96–111PubMedCrossRef Erickson VS, Pearson ML, Ganz PA et al (2001) Arm edema in breast cancer patients. J Natl Cancer Inst 93:96–111PubMedCrossRef
12.
Zurück zum Zitat Szuba A, Achalu R, Rockson SG (2002) Decongestive lymphatic therapy for patient with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 95(11):2260–2267PubMedCrossRef Szuba A, Achalu R, Rockson SG (2002) Decongestive lymphatic therapy for patient with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 95(11):2260–2267PubMedCrossRef
13.
Zurück zum Zitat Johansson K, Ohlsson K, Ingvar C et al (2002) Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology 35:59–71PubMed Johansson K, Ohlsson K, Ingvar C et al (2002) Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology 35:59–71PubMed
14.
Zurück zum Zitat Petrek JA, Senie RT, Peters M et al (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92:1368–1377PubMedCrossRef Petrek JA, Senie RT, Peters M et al (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92:1368–1377PubMedCrossRef
15.
Zurück zum Zitat Sestak I, Harvie M, Howell A et al (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134:727–734PubMedCrossRef Sestak I, Harvie M, Howell A et al (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134:727–734PubMedCrossRef
16.
Zurück zum Zitat Cutuli B, Aristei C, Martin C et al (2004) Breast-conserving therapy for stage I-II breast cancer in elderly women. Int J Radiat Oncol Biol Phys 60(1):71–76PubMedCrossRef Cutuli B, Aristei C, Martin C et al (2004) Breast-conserving therapy for stage I-II breast cancer in elderly women. Int J Radiat Oncol Biol Phys 60(1):71–76PubMedCrossRef
Metadaten
Titel
Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema
verfasst von
Sibel Eyigör
Ece Cinar
Ismail Caramat
Burcu Koc Unlu
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2633-9

Weitere Artikel der Ausgabe 9/2015

Supportive Care in Cancer 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.